RecruitingNCT03775954

Fetal Electrophysiologic Abnormalities in High-Risk Pregnancies Associated With Fetal Demise

Fetal Electrophysiologic Abnormalities in High-risk Pregnancies Associated With Fetal Demise

Sponsor

Medical College of Wisconsin

Enrollment

30 participants

Start Date

Jul 1, 2018

Study Type

OBSERVATIONAL

Conditions

gastroschisis Fetal death Pregnancy Loss Congenital Heart Disease Twin Monochorionic Monoamniotic Placenta Long QT Syndrome Brugada Syndrome Stillbirth High Risk Pregnancy Sudden Infant Death Fetal Arrhythmia Fetal Cardiac Disorder Fetal Hydrops Birth Defect Fetal Demise Twin Twin Transfusion Syndrome Fetal Cardiac Anomaly Fetal Tachycardia Intrauterine fetal death

Summary

Each year world-wide, 2.5 million fetuses die unexpectedly in the last half of pregnancy, 25,000 in the United States, making fetal demise ten-times more common than Sudden Infant Death Syndrome. This study will apply a novel type of non-invasive monitoring, called fetal magnetocardiography (fMCG) used thus far to successfully evaluate fetal arrhythmias, in order to discover potential hidden electrophysiologic abnormalities that could lead to fetal demise in five high-risk pregnancy conditions associated with fetal demise.

Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Fetal Magnetocardiogram and Neonatal Electrocardiogram and Substudy only: Maternal/Infant Pharmacogenomic assessment postnatally for people with birth defect, brugada syndrome, and other related conditions. The study is currently recruiting participants at 2 locations. People eligible for this study include women aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTFetal Magnetocardiogram and Neonatal Electrocardiogram

Fetal Magnetocardiography (fMCG) is a new non-invasive diagnostic procedure that records tiny fetal cardiac signals similar to an Electrocardiogram or Holter monitor. The magnetometer has FDA clearance, and does not emit magnetic, electric or other energies. This is not an MRI. Examples of fetal MCG's can be found in the Links. The American Heart Association Scientific Statement on Fetal Diagnosis and Treatment (Circulation, 2014) has declared fMCG to be Class IIa for fetal heart rhythm abnormalities, meaning that benefit far exceeds risk. As part of this study, a neonatal electrocardiogram (nECG) will be obtained for comparison after the baby is born.

GENETICSubstudy only: Maternal/Infant Pharmacogenomic assessment postnatally

See also section 6. Pharmacogenomics measure the way the liver breaks down medications. The systems controlling this are inherited, and mothers or infants can be normal, fast, ultrafast, or poor metabolizers for certain drugs. This study will attempt to improve future safety of cardiac drug treatments for both mother and fetus by evaluating the impact of PG.

Locations(2)

University of Wisconsin - Madison

Madison, Wisconsin, United States

Medical College of Wisconsin

Milwaukee, Wisconsin, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03775954

Related Trials

Screening for Disorders of Lipid Metabolism and Familial Hyperlipidemia in Children and Adolescents With Increased Cardiovascular Risk Due to Chronic Diseases Such as Congenital Heart Disease, Chronic Inflammatory Bowel Disease, Celiac Disease and Rheumatic Disorders

NCT077164881 location

Fontan Associated Liver Disease and the Evaluation of Biomarkers for Disease Severity Assessment

NCT052135981 location